European Parliament Signs Off Regulation To Tackle Medicine Shortages
The legislation will establish a new EU platform for monitoring and reporting medicines shortages.
You may also be interested in...
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.
New pandemic-related responsibilities have been entrusted to the European Medicines Agency by a regulation published on 31 January. They include coordinating vaccine safety and effectiveness studies and setting up a European network of real-world data to help support health crisis preparedness and response.
Two EU institutions have reached a deal on legislation that will give the EMA a key tool for monitoring medicines supply and preventing shortages in the event of a major public health crisis such as a future pandemic.